SCHEMBL25637697

SCHEMBL25637697

O=[N+]([O-])c1c(Br)ccc2nccnc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
TYMS P04818 1/20 0.40
NPY1R P25929 1/20 0.36
ADRA2A P08913 2/20 0.36
USP2 O75604 1/20 0.36
KEAP1 Q14145 1/20 0.36
NFE2L2 Q16236 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
PDE10A Q9Y233 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
POLB P06746 1/20 0.34
NQO2 P16083 1/20 0.34
CYP1A2 P05177 1/20 0.34
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30592428 0.80 MEN1 (0.65) MEN1KMT2AADRA2BADRA2CPDE10A
SCHEMBL12813932 0.79 MEN1 (0.63) MEN1KMT2ANPY1RUSP2KEAP1
SCHEMBL18083010 0.79 MEN1 (0.68) MEN1KMT2ANPY1RADRA2AUSP2
Methane SCHEMBL28139150 0.77 MEN1 (0.61) MEN1KMT2ANPY1RUSP2KEAP1
SCHEMBL4079065 0.76 POLB (0.54) MEN1KMT2ANPY1RADRA2BADRA2C
SCHEMBL10277259 0.75 KMT2A (0.62) MEN1KMT2AADRA2AADRA2BADRA2C
SCHEMBL34472003 0.74 MAPT (0.60) MEN1KMT2ATYMSUSP2KEAP1
SCHEMBL3469093 0.73 ALDH1A1 (0.44) TYMSTSHRPMM2MPIALDH1A1
SCHEMBL31182415 0.72 MEN1 (0.46) MEN1KMT2ANPY1RADRA2BADRA2C
SCHEMBL20471933 0.72 MEN1 (0.53) MEN1KMT2ATYMSNPY1RPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219986-A1 NOVEL AMINOPYRIMIDINE EGFR INHIBITOR QILU PHARMACEUTICAL CO., LTD. (CN) 2023-07-13 US disclosed
US-20230219986-A1 NOVEL AMINOPYRIMIDINE EGFR INHIBITOR QILU PHARMACEUTICAL CO., LTD. (CN) 2023-07-13 US disclosed
US-20230192734-A1 TRICYCLIC COMPOUNDS AS EGFR INHIBITORS QILU PHARMACEUTICAL CO LTD (CN) 2023-06-22 US disclosed
WO-2022059778-A1 CYCLIC UREA DERIVATIVE カルナバイオサイエンス株式会社 2022-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192734-A1 TRICYCLIC COMPOUNDS AS EGFR INHIBITORS EGFR, ERBB2, ERBB3 MEN1 2200/4885KMT2A 3421/4885TYMS 364/4885
US-20230219986-A1 NOVEL AMINOPYRIMIDINE EGFR INHIBITOR EGFR, ERBB2, ERBB4 MEN1 4348/4885KMT2A 1471/4885TYMS 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.